Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqCM - Nasdaq Real Time Price USD

ReShape Lifesciences Inc. (RSLS)

Compare
0.4500
-1.1400
(-71.70%)
At close: April 2 at 4:00:01 PM EDT
0.4100
-0.04
(-8.89%)
Pre-Market: 7:21:01 AM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Dan W. Gladney Executive Chair 129.5k -- 1953
Mr. Paul F. Hickey CEO, President & Director 506.42k -- 1965
Mr. Thomas Stankovich Senior VP & CFO 307.12k -- 1961
Mr. Al Diaz Vice President of Operations and R&D -- -- --
Dr. Dov Gal D.V.M., M.B.A. VP of Regulatory Clinical Quality & Compliance Officer -- -- --
Mr. Naqeeb A. Ansari Senior Vice President of Global Commercial Operations 327.46k -- 1961

ReShape Lifesciences Inc.

18 Technology Drive
Suite 110
Irvine, CA 92618
United States
949 429 6680 https://www.reshapelifesciences.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
29

Description

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

Corporate Governance

ReShape Lifesciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 3, 2025 at 10:59 AM UTC - April 4, 2025 at 12:00 PM UTC

ReShape Lifesciences Inc. Earnings Date

Recent Events

April 2, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 1, 2025 at 12:00 AM UTC

NT 10-K: Periodic Financial Reports

March 20, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 14, 2025 at 12:00 AM UTC

DEF 14A: Proxy Statements

March 13, 2025 at 12:00 AM UTC

PRER14A: Proxy Statements

February 20, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 14, 2025 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

February 13, 2025 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

February 12, 2025 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

February 7, 2025 at 12:00 AM UTC

S-1/A: Offering Registrations

Related Tickers